Slynd (Drospirenone) Patent Expiration, LOE Window & CMS Spending

Slynd (Drospirenone) by Exeltis Usa: FDA Orange Book LOE 2031-06-28, 0 AB generics, $62.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorExeltis Usa
FDA Application & PathwayN211367 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-06-28
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$62.0M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$60.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel